Profound Medical Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Profound Medical şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-12.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-12.3%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Here's Why We're Not Too Worried About Profound Medical's (TSE:PRN) Cash Burn Situation

Jan 07

We Think Profound Medical (TSE:PRN) Can Easily Afford To Drive Business Growth

Jul 02

We Take A Look At Why Profound Medical Corp.'s (TSE:PRN) CEO Compensation Is Well Earned

May 13

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: PRN şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: PRN şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Profound Medical Piyasaya Karşı Temettü Getirisi

PRN temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (PRN)	n/a
Pazarın Alt %25'i (CA)	1.8%
Pazarın En İyi %25'i (CA)	6.2%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (PRN) (3 yıla kadar)	n/a

Önemli Temettü: PRN şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, PRN şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: PRN şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: PRN herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Profound Medical Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Profound Medical Corp. Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System Final Rule for CY2025

Profound Medical Corp. to Report Q3, 2024 Results on Nov 07, 2024

Chairman of the Board & CEO exercised options to buy CA$176k worth of stock.

Chairman of the Board & CEO exercised options to buy CA$210k worth of stock.

Chief Financial Officer recently bought CA$125k worth of stock

New minor risk - Profitability

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Profound Medical Corp. to Report Q2, 2024 Results on Aug 08, 2024

Profound Medical Corp. Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases

Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan

New minor risk - Profitability

Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024

Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024

First quarter 2024 earnings released: US$0.26 loss per share (vs US$0.32 loss in 1Q 2023)

Forecast to breakeven in 2026

Does Profound Medical (TSE:PRN) Have A Healthy Balance Sheet?

Profound Medical Corp. to Report Q1, 2024 Results on May 09, 2024

Chief Commercial Officer of US recently sold CA$95k worth of stock

Chief Commercial Officer of US notifies of intention to sell stock

Profound Medical Corp., Annual General Meeting, May 15, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Profound Medical Corp. to Report Q4, 2023 Results on Mar 07, 2024

Profound Medical Corp. announced that it expects to receive $2.937503 million in funding

Profound Medical Corp. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

Profound Medical Corp. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

Profound Medical Corp. Announces CMD Extension of Temporary Code for TULSA to ASC Setting

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Profound Medical Corp. to Report Q3, 2023 Results on Nov 02, 2023

Profound Medical Corp. Receives U.S. FDA 510(k) Clearance for TULSA-PRO Thermal Boost

Is Profound Medical (TSE:PRN) Using Debt In A Risky Way?

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Profound Medical Corp. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Shareholder dilution

Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS and revenues miss analyst expectations

Profound Medical Corp. to Report Q4, 2022 Results on Mar 07, 2023

Chairman & CEO recently bought CA$138k worth of stock

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Profound Medical Corp. to Report Q3, 2022 Results on Nov 03, 2022

Profound Medical Corp. Announces Updated Results from the TACT (TULSA-PRO® Ablation Clinical Trial)

Profound Medical Corp. Announces Changes to Commercial Organization to Support Continued Growth

Will Profound Medical (TSE:PRN) Spend Its Cash Wisely?

Profound Medical Corp. Provides TULSA-PRO Reimbursement Update

Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.35 loss in 2Q 2021)

Profound Medical Corp. to Report Q2, 2022 Results on Aug 04, 2022

Independent Director recently bought CA$123k worth of stock

Profound Medical Corp. Elects Kris Shah to Board of Director

Profound Medical Corp. Unveils TULSA-PRO Software Release 2.11, Which Includes Two New Features

Independent Lead Director recently bought CA$459k worth of stock

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Profound Medical Corp. to Report Q1, 2022 Results on May 09, 2022

Chairman & CEO recently bought CA$637k worth of stock

Forecast to breakeven in 2024

No longer forecast to breakeven

Profound Medical Corp. Confirms the TULSA-PRO Systems New Compatibility with GE Healthcares 3T

Profound Medical Corp. to Report Q4, 2021 Results on Mar 03, 2022

Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the Tulsa Procedure to Radical Prostatectomy

Here's Why We're Not Too Worried About Profound Medical's (TSE:PRN) Cash Burn Situation

Forecast to breakeven in 2024

Chairman & CEO recently bought CA$125k worth of stock

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.33 loss in 3Q 2020)

Chairman & CEO exercised options to buy CA$634k worth of stock.

Independent Director recently bought CA$127k worth of stock

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.33 loss in 2Q 2020)

No longer forecast to breakeven

Consensus forecasts updated

We Think Profound Medical (TSE:PRN) Can Easily Afford To Drive Business Growth

Price target decreased to CA$29.55

Independent Director has left the company

Independent Lead Director recently bought CA$387k worth of stock